Observational studyBMC ophthalmology2026
Serial aqueous VEGF analysis for predicting anti-VEGF treatment outcomes in neovascular glaucoma from diabetic retinopathy: a prospective analysis.
Observational study in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This study evaluated the clinical outcomes of intravitreal bevacizumab (IVB) in neovascular glaucoma (NVG) secondary to proliferative diabetic retinopathy (PDR) and investigated the association between serial aqueous vascular endothelial growth factor (VEGF) levels and treatment outcomes. A prospective single-arm observational study included 17 patients with NVG due to PDR. All patients received three bi-weekly IVB injections. Aqueous VEGF levels, intraocular pressure (IOP), and best-corrected visual acuity (BCVA) were measured before and after each injection. After the initial three injections, additional IVB injections were administered on a pro re nata (PRN) basis if IOP exceeded 21 mmHg or if iris or angle neovascularization persisted or recurred. Patients were followed for up to 3 years. After three injections, mean VEGF levels significantly decreased from 4681.46 pg/mL to 104.55 pg/mL (P < 0.001). BCVA improved (1.27 to 0.91 LogMAR, P < 0.001), and IOP decreased from (32.71 to 25.29 mmHg, p = 0.031). Higher baseline VEGF levels were significantly associated with worse BCVA and elevated IOP after treatment, as well as more frequent injections. Patients requiring six or more injections showed significantly higher baseline VEGF levels and poorer clinical outcomes compared to those requiring five or fewer injections. Serial aqueous VEGF levels were significantly associated with clinical outcomes and treatment burden in NVG secondary to PDR. Aqueous VEGF may serve as a potential surrogate marker reflecting disease severity and therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.